Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DiagnostykaFRA:7JS +2.13%18 EV-to-EBITDA is 11.62 as of Jul. 21, 2026, which is 1% below its 10-year median of 11.79. GuruFocus rates FRA:7JS with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 117 Medical Diagnostics & Research companies, Diagnostyka ranks better than 61.54% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Diagnostyka's enterprise value is €1,618.6 Mil.
Diagnostyka's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €139.3 Mil. Therefore, Diagnostyka's EV-to-EBITDA for today is 11.62.
The historical rank and industry rank for Diagnostyka's EV-to-EBITDA or its related term are showing as below:
FRA:7JS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.12 Med: 11.79 Max: 14.81
Current: 11.41
During the past 5 years, the highest EV-to-EBITDA of Diagnostyka was 14.81. The lowest was 10.12. And the median was 11.79.
FRA:7JS's EV-to-EBITDA is ranked better than 61.54% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 14.55
vs FRA:7JS: 11.41
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Diagnostyka (FRA:7JS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Diagnostyka's PE Ratio (TTM) for today is calculated as:
Diagnostyka's share price for today is €39.36.
Diagnostyka's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.767.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Diagnostyka's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7JS vs TMO, DHR, IDXX: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Diagnostyka's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diagnostyka EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diagnostyka's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Diagnostyka's EV-to-EBITDA falls into.
Diagnostyka's current Enterprise Value is €1,618.6 Mil.
Diagnostyka's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €139.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diagnostyka (FRA:7JS) has a EV-to-EBITDA of 11.62 as of Jul. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Diagnostyka. This is near median its historical median of 11.79. Over the past decade, Diagnostyka's EV-to-EBITDA has ranged from 10.12 to 14.81. According to the industry distribution chart, Diagnostyka ranks #45 out of 117 companies in the Medical Diagnostics & Research industry, placing it in the top 38.5%.
Is Diagnostyka's EV-to-EBITDA too high?
Diagnostyka's current EV-to-EBITDA of 11.62 is near median its 10-year median of 11.79. Over the past 10 years, this metric has ranged from a low of 10.12 to a high of 14.81. The Medical Diagnostics & Research industry median EV-to-EBITDA is 14.55. Diagnostyka's value of 11.62 is 20.1% below this industry median. Based on the distribution chart, Diagnostyka ranks #45 out of 117 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Diagnostyka has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Diagnostyka's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diagnostyka ranks #45 out of 117 companies for EV-to-EBITDA. This puts Diagnostyka in the upper half of its industry. The industry median EV-to-EBITDA is 14.55. Diagnostyka's value of 11.62 is 20.1% below this benchmark. Historically, Diagnostyka's own EV-to-EBITDA has ranged from 10.12 to 14.81 over the past decade. While the company's 10-year median is 11.79 vs. the industry median of 14.55, Diagnostyka has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 14.55, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diagnostyka's current EV-to-EBITDA of 11.62 is 20.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Diagnostyka. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 14.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnostyka's current EV-to-EBITDA is 11.62, which is near median its own 10-year median of 11.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnostyka stock overvalued right now?
Diagnostyka (FRA:7JS) has a current EV-to-EBITDA of 11.62. The current EV-to-EBITDA is 11.62, which is near median its 10-year median of 11.79 and 20.1% below the Medical Diagnostics & Research industry median of 14.55. Diagnostyka's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Diagnostyka (FRA:7JS), the current EV-to-EBITDA is 11.62 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Diagnostyka SA is engaged in providing laboratory diagnostics services in Poland. The company offers comprehensive laboratory services from collecting biological material, through testing, to providing results online.
18GF Score
Get the complete analysis for FRA:7JS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7JS has been successfully added to your 
